



20202578
#29153989.3

IRB Approved at the
Protocol Level
Mar 30, 2022

Sponsored by Sanofi

Dear Sjögren's Patient:

We are pleased to share information about a new clinical research study already enrolling in your area for individuals with Sjögren's. Your participation in this study could help future patients worldwide.

This new study, ACT16618, is looking for individuals diagnosed with Sjögren's within the last 15 years, who have no other autoimmune disease such as lupus or rheumatologic condition (rheumatoid arthritis). The only autoimmune disease, which you may have and still be eligible is hashimoto thyroiditis. Patients can be male or female and between the ages of 18 and 80 years of age. With some restrictions, patients may be able to continue taking medications during the study such as:

- oral corticosteroids
- chloroquine treatment
- nonsteroidal anti-inflammatory medications
- topical medications
- treatments for dryness of mouth
- Vitamin D
- Levothyroxine
- and others

Study drug and study-related care will be available to eligible participants as well as travel related cost as needed.

For more information and to see if you may be eligible to participate please contact:

Dr. Biruh Workeneh
Prolato Clinical Research Center
8990 Kirby Drive, Suite 240
Houston, TX 77054

To learn more call Alice Winstead, Clinical Trial Coordinator at (832) 338-9118 or email awinstead@prolato.org

On behalf of the millions of Sjögren's sufferers in this country, I thank you for taking time to learn more about this study.

Sincerely,

A handwritten signature in black ink, appearing to read "Janet Church", written in a cursive style.

Janet Church
President and Chief Executive Officer

Note: You received this notice because of your participation and/or interest in the Sjögren's Foundation. The Foundation sends this research notice for information only. It does not represent an endorsement of this study but only makes you aware of this research project for your participation if you choose.